Lilly, Howson long-term GLP-1 health care price outflow! After the national harvest, the original research and selection of drugs also reduced prices

Under the influence of health care negotiations and volume purchase, a number of heavy drugs recently announced price cuts.
saccharide injections, polyglycol locena peptide injections, baritinib tablets, capertabin tablets... Lilly, Haussen long-term GLP-1 medical insurance price suspected exposure January 13, Shaanxi Province Public Resources Trading Center issued a notice that, according to the enterprise application, Lilly lactose peptide injection (1.5mg: 0.5ml pre-filled injection pen, 2 units / box) hanging net limit price from 840 yuan / box to 298 yuan / box, that is, 149 yuan each.
fell by more than 64.5 per cent.
January 12, Shaanxi Provincial Public Resources Trading Center issued a notice on adjusting the price limit for some products, according to the enterprise application, Jiangsu Haussen polyglycol locena peptide injection (spec: 0.5ml: 0.2mg / Branch) hanging net limit price from 395 yuan / branch adjusted to 187 yuan / branch, Beijing Science Park Xinhai Pharmaceutical Management Co. , Ltd. agent of the fluorine for meiwei inhalation powder foggy net limit price from 900 yuan / box adjusted to 239 yuan / box.
coincidence, just the day before, Jilin Province also issued a notice to reduce the price of Jiangsu Haussen polyglycol losena peptide injection, Haussen Pharmaceuticals polyglycol losena peptide injection (spec: 0.5ml: 0.1mg) hanging net limit price from 295 yuan / box to 110 yuan / box, the product another Specification 0.5ml: 0.2mg of the limit price of the hanging net from 395 yuan / box to 187 yuan / box, the same day, Henan Province also issued the adjustment of Barrettini tablets, polylactic peptide injection and fluoride meth inhalation powder fog agent 3 drugs hanging limit price notice, adjusted price from January 13, 2021.
adjusted prices have not been announced.
It is worth noting that the dose of glycosine injection, polyglycol locena peptide injection, Barrettini tablets, fluorotinavi inhalation powder mist, etc. have just been transferred to the health care directory through health care negotiations, the new payment price is expected to be formally implemented in March this year, and the negotiating price due to non-disclosure agreement has not yet been announced, at this time the major enterprises in the provinces to lower prices, it is very likely that the market strategy after the negotiations, and at this time the network price is likely to be the result of negotiations.
, after all, is close to the March landing implementation, the price announcement is only a matter of morning and evening.
data show that glucagon-like peptide 1 (GLP-1) is a natural secretion of the body's gastrointestinal mucosa of a "intestinal-promoting tryptoprene", which can bind to the islet cells and stimulate insulin secretion, which in turn produces a lower blood sugar effect.
GLP-1-1-subjected astrogenic antisaccharides include short-acting and long-lasting drugs.
Currently a total of 7 GLP-1 approved for the market, of which short-acting products are Essena peptide, benaglutide, Lisna peptide;
the short-acting GLP-1 liraglutide was included in the 2017 version of the health insurance catalog for $410 per branch and successfully renewed for the 2019 edition of the health insurance catalog, and Lisnapeptide and Essena peptide were included in the 2019 version of the health insurance catalog.
lead the way in cutting prices in the provinces, Lilly's polysaccharide peptides and Haussen's polyglycol lorcena peptides belong to the same long-acting GLP-1-1-subjector agitants.
February 2019, Lilly's saccharide peptides were approved for listing in China at a original price of 420 yuan per branch (1.5mg:0.5ml, pre-filled injection pen), injected once a week.
If the price is negotiated for medical insurance according to the price reduction in Shaanxi Province, the annual cost of using an ordinary patient (52 weeks) is 7,769 yuan, according to the 70% reimbursement ratio, the individual is only 2,331 yuan / year, the monthly cost of 149 yuan.
's polyethyl glycol lorcena peptide was approved for sale on May 6, 2019, and the product has undergone more than 10 years of development since it was approved for clinical listing on October 8, 2008.
2020 Health Insurance Directory, benaglutide, syraglutide and polyglycol locena peptides were successfully negotiated.
, a total of six GLP-1s have been included in the health insurance list.
under the medical insurance catalog and volume procurement, the price of various types of diabetes drugs to meet and expand the demand for patients, GLP-1 market competition is also quite fierce.
In addition, Lilly also recently announced that another anti-rheumatoid arthritis target drug Elamine ® (Barrettini tablets) 2mg tablets in advance to adjust the factory price, so that the end-of-drug prices can be reduced to the level of health insurance as soon as possible.
we are not aware of the specific reduction due to the confidentiality of the price.
the national collection, the original research and selection of enterprises also fell! In addition to the health care negotiations varieties to take the lead in reducing prices, the third batch of national varieties in 2020 has also recently come to the news of price cuts.
January 12, Shanxi Province Pharmaceutical Equipment Centralized Tendering and Purchasing Center issued a notice on sichuan Huiyu Pharmaceutical Co., Ltd. and other three enterprises online drug procurement reference price adjustment notice (Jin Pharmaceutical Recruitment (2021) No. 2).
Among them, Sichuan Huiyu Pharmaceutical Co., Ltd. produced 100 mg of injection Aza cysine procurement reference price adjusted to 260 yuan / bottle;
In August 2020, the third batch of national tenders, injection of Aza cytosine finally by Sichuan Huiyu and Zhengda Tianqing winning the bid, Sichuan Huiyu supply provinces do not have Shanxi Province, this time in Shanxi Province price reduction, you can see that after the collection of price linkage phenomenon has been very common.
the third batch of state-owned bidding, the original pharmaceutical companies in the maintenance of the global price system and large-scale "retreat" has also attracted the attention of the industry, but for the selected varieties, homeopathy price reduction is the long-term survival of the way.
Capatabin tablet is Roche's original drug, with global sales of $1.827 billion in 2019.
data show that the size of capedabin tablets in China's hospital terminal market reached 2.568 billion yuan, in the domestic market dominated by the original research, accounting for more than 70%.
in last year's bidding, Caperthabin tablets 0.5g maximum effective declared price of 7.6667, Roche quoted 298 yuan (12 pieces / box), equivalent to 24.8 yuan, Hengrui Pharmaceuticals quoted 3.379 ... The end result is the success of Hengrui Pharmaceuticals and Qilu Pharmaceutical's Capetabin tablets, Qilu down 70%, Hengrui down 55.9%, these two products are also in early 2020 through a consistent evaluation, after the collection will be expected to "grab" Roche's corresponding market.
, according to the first-line oncologist, the original Capethabin tablets a piece of 15 yuan, a box of about 150 yuan.
the highest decline in the third batch of countries, patients can save more than 11,000 yuan in the cost of treatment for a treatment cycle (about half a year).
In addition, in 2020, Jilin Provincial Public Resources Trading Center issued a "notice on the publicity of the third batch of national organizations centralized procurement and use of drugs not selected Jilin Province and not selected and has participated in Jilin Province to register the procurement of some drug prices linked price reduction results."
not selected and has participated in Jilin Province to purchase some of the drug prices linked price reduction results, Roche's Capetabin tablets (commodity name: Hiroda) public price limit is also 264.25 yuan / box.
Although some of the original pharmaceutical companies in the collection of "elimination"-style bidding, but still difficult to escape the unelested price linkage, hanging net limit price is significantly lower than the bid in the enterprise declared price, and enterprises do not lose with this price will be the entire hospital market.